110 related articles for article (PubMed ID: 30246955)
21. Vitamin D status and risk for malignant cutaneous melanoma: recent advances.
Ombra MN; Paliogiannis P; Doneddu V; Sini MC; Colombino M; Rozzo C; Stanganelli I; Tanda F; Cossu A; Palmieri G
Eur J Cancer Prev; 2017 Nov; 26(6):532-541. PubMed ID: 28125434
[TBL] [Abstract][Full Text] [Related]
22. [The prognostic role of clinical factors, VEGF, IL-8 and sTNF-R1 in cutaneous melanomas at locoregional stage].
Ługowska I; Kowalska M; Zdzienicki M; Fuksiewicz M; Kamińska J; Szamotulska K; Rutkowski P
Pol Merkur Lekarski; 2012 Jan; 32(187):22-7. PubMed ID: 22400175
[TBL] [Abstract][Full Text] [Related]
23. Current staging and prognostic factors in melanoma.
Bartlett EK; Karakousis GC
Surg Oncol Clin N Am; 2015 Apr; 24(2):215-27. PubMed ID: 25769707
[TBL] [Abstract][Full Text] [Related]
24. 25-Hydroxyvitamin D in Patients With Melanoma and Factors Associated With Inadequate Levels.
Hernández-Ostiz S; Pérez-Ramada MD; Ortiz B; Requena C; Ribas G; Aznar E; Nagore E
Actas Dermosifiliogr; 2016 Nov; 107(9):758-764. PubMed ID: 27418183
[TBL] [Abstract][Full Text] [Related]
25. High serum 25-hydroxyvitamin D concentration in patients with a recent diagnosis of non-melanoma skin cancer: a case-control study.
Soares AM; Szejnfeld VL; Enokihara MY; Michalany N; Castro CH
Eur J Dermatol; 2018 Oct; 28(5):649-653. PubMed ID: 30355545
[TBL] [Abstract][Full Text] [Related]
26. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
Li J; Fu W; Zhang W; Li P
Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
[TBL] [Abstract][Full Text] [Related]
27. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
Desch A; Gebhardt C; Utikal J; Schneider SW
Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
[TBL] [Abstract][Full Text] [Related]
28. Response.
Saiag P; Aegerter P; Boniol M
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26912670
[No Abstract] [Full Text] [Related]
29. No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival.
Luo L; Orlow I; Kanetsky PA; Thomas NE; Fang S; Lee JE; Berwick M; Lee JH;
PLoS One; 2017; 12(3):e0174234. PubMed ID: 28323902
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
[TBL] [Abstract][Full Text] [Related]
31. In praise of small studies.
Diffey BL
Br J Dermatol; 2011 Jul; 165(1):3-4. PubMed ID: 21707572
[No Abstract] [Full Text] [Related]
32. Melanoma risk is associated with vitamin D receptor gene polymorphisms.
Zeljic K; Kandolf-Sekulovic L; Supic G; Pejovic J; Novakovic M; Mijuskovic Z; Magic Z
Melanoma Res; 2014 Jun; 24(3):273-9. PubMed ID: 24638155
[TBL] [Abstract][Full Text] [Related]
33. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.
Kanemaru H; Fukushima S; Yamashita J; Honda N; Oyama R; Kakimoto A; Masuguchi S; Ishihara T; Inoue Y; Jinnin M; Ihn H
J Dermatol Sci; 2011 Mar; 61(3):187-93. PubMed ID: 21273047
[TBL] [Abstract][Full Text] [Related]
34. Tumor biomarkers in melanoma.
Ugurel S; Utikal J; Becker JC
Cancer Control; 2009 Jul; 16(3):219-24. PubMed ID: 19556961
[TBL] [Abstract][Full Text] [Related]
35. Serum total gangliosides level: clinical prognostic implication.
Nicolae I; Nicolae CD; Coman OA; Stefănescu M; Coman L; Ardeleanu C
Rom J Morphol Embryol; 2011; 52(4):1277-81. PubMed ID: 22203934
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
37. Vitamin D status and skin cancer risk independent of time outdoors: 11-year prospective study in an Australian community.
van der Pols JC; Russell A; Bauer U; Neale RE; Kimlin MG; Green AC
J Invest Dermatol; 2013 Mar; 133(3):637-641. PubMed ID: 23076499
[TBL] [Abstract][Full Text] [Related]
38. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
39. Higher serum 25-hydroxy vitamin D3 levels at presentation are associated with improved survival from melanoma, but there is no evidence that later prevailing levels are protective.
Hutchinson PE; Osborne JE; Pringle JH
J Clin Oncol; 2010 Sep; 28(27):e492-3; author reply 494-5. PubMed ID: 20625133
[No Abstract] [Full Text] [Related]
40. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients.
Farthmann B; Eberle J; Krasagakis K; Gstöttner M; Wang N; Bisson S; Orfanos CE
J Invest Dermatol; 1998 Mar; 110(3):263-7. PubMed ID: 9506446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
